潜伏转化生长因子β-结合蛋白1/转化生长因子β1复合驱动对黑色素瘤中的ERK5向对抗瘤效应
Alessandro Tubita1, Alessio Menconi1, Zoe Lombardi1
1Department of Clinical and Experimental Biomedical Sciences, University of Florence, Florence, Italy.
The American journal of pathology
|May 5, 2024
概括
抑制黑色素瘤中的细胞外信号调节激酶5 (ERK5) 抑制潜伏转化生长因子β结合蛋白1 (LTBP1) 和转化生长因子β (TGF-β1). 这促进了瘤抑制和更好的患者存活率,特别是在抗PD1疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 黑色素瘤是一种侵袭性皮肤癌,晚期的治疗选择有限.
- 细胞外信号调节激酶5 (ERK5) 驱动黑色素瘤的进展.
- 抑制ERK5会诱导细胞衰老,并改变瘤的微环境.
研究的目的:
- 研究ERK5抑制在黑色素瘤中的作用.
- 为了确定黑色素瘤中ERK5的下游点.
- 探索向黑色素瘤中的ERK5的治疗潜力.
主要方法:
- 使用了具有BRAF V600E突变的黑色素瘤细胞系 (A375,SK-Mel-5).
- 进行了ERK5和LTBP1敲击 (KD) 实验.
- 用ERK5抑制剂 (XMD8-92) 给小鼠的黑色素瘤异种移植.
- 分析了LTBP1和TGF-β1.1的蛋白质和mRNA水平.
- 评估了细胞增殖和侵入性.
- 与患者生存数据相关的基因表达.
主要成果:
- 在黑色素瘤细胞中,ERK5抑制上调了潜伏转化生长因子β结合蛋白1 (LTBP1) mRNA.
- 转化生长因子β (TGF-β1) 蛋白水平在ERK5抑制时增加,在LTBP1敲击时降低.
- 在用ERK5抑制剂治疗的异种移植中,LTBP1和TGF-β1蛋白在体内升高.
- 来自ERK5抑制细胞的条件介质降低了黑色素瘤细胞的增殖和侵入性,这种效应因TGF-β1中和而减弱.
- 在黑色素瘤患者中,较高的LTBP1和TGF-β1mRNA表达与改善的整体存活率相关.
- 这些因素在接受抗PD1免疫治疗的患者中起到了有益的作用.
结论:
- 在黑色素瘤中,ERK5抑制促进了抑制瘤的TGF-β1通路.
- LTBP1是ERK5抑制对TGF-β1.1影响的关键媒介.
- 针对ERK5通过增强TGF-β1信号传递,提供了潜在的治疗益处.
- 升高的LTBP1和TGF-β1是有利的预后标志物,可以提高免疫治疗的疗效.
更多相关视频
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
8.7K
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
2.9K
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
